Click to Share
 

Biopharmaceuticals Press Releases

Exclusive News
Topics Locations Industries Dates

By Biomed Industries Inc.
Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation.
By Xheme, Inc.
Could one additive improve yield across the entire bioprocessing industry, decrease the cost of biopharmaceuticals, increase the quality and safety of cell therapies, and even help eliminate animal testing? Yes, if it's the Xheme Multifunctional Additive.

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share